Applied Genetic Technologies agtc.com


Public list: Pharma Startups (4743) Eye Health (701) Rare Diseases (230)

Applied Genetic Technologies Corporation is focused on developing gene therapy products derived from adeno-associated virus (AAV) for the treatment of inherited and acquired diseases. AGTC's lead product candidate is a treatment for Alpha One Antitrypsin Deficiency (Alpha-1). AGTC's treatment for Alpha-1, a debilitating respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin (AAT), has an outstanding safety profile in two Phase I human clinical trials co...Show all

Applied Genetic Technologies Corporation is focused on developing gene therapy products derived from adeno-associated virus (AAV) for the treatment of inherited and acquired diseases. AGTC's lead product candidate is a treatment for Alpha One Antitry...Show all

Company (IPO / Went public)

Phone: 386-462-2204

Fax: (386) 462-7396

14193 NW 119th Terrace
Suite 10
Alachua, 32615
Florida, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Applied Genetic Technologies $109.2M Mar 27, 2014
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Applied Genetic Technologies Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 11 investors

Competitors

Company Status Description Investors

Cognition Therapeutics

Pittsburgh, Pennsylvania, United States
Alive / ActiveCognition Therapeutics is focused on the discovery and development of small molecule therapeutics targeting toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large number of human diseases, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the combination of biological expert...Show allLogin to see details

Xenon Pharmaceuticals

Burnaby, British Columbia, Canada
IPO / Went publicXenon Pharmaceuticals is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. The company has built a core platform, Extreme Genetics, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mut...Show allLogin to see details
See all 15 competitors